Teva loses US appeal to keep inhaler patents on FDA protected drug list December 20, 2024 Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free ...

(Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a prominent player in the generic and specialty pharmaceutical industry with a market capitalization of $2.45 billion, has been making significant ...

Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus, driven by strong launches and specialty growth.

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva ...